We suggest you to use CR Bard Inc fundamental analysis to see if markets are at this moment mispricing the company. Strictly speaking you can use it to find out if CR Bard Inc is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found thirty-eight available financial indicators for CR Bard which can be compared to its peers in the sector. To make sure the equity is not overpriced, please confirm all CR Bard Inc fundamentals including its Current Valuation, Revenue, Current Ratio, as well as the relationship between Number of Shares Shorted and Cash and Equivalents . Given that CR Bard Inc has Price to Earning of 75.72 times, we suggest you validate CR Bard latest market performance to make sure the company can sustain itself this quarter and beyond.
CR Bard Price to Sales vs Total Debt
CR Bard Inc is rated fifth in price to sales category among related companies. It is rated below average in total debt category among related companies making up about 417,827,298 of Total Debt per Price to Sales.
CR Bard competes with BAXTER, COVIDIEN, BECTON, CareFusion, and DENTSPLY. CR Bard Inc offers vascular products such as percutaneous transluminal angioplasty catheters chronic total occlusions catheters guidewires fabrics meshes introducers and accessories peripheral vascular stents covered stents and vascular grafts vena cava filters biopsy devices and drug coated balloon devices to treat peripheral vascular disease and heart arrhythmias. Its urology solutions comprise Foley catheters to reduce the rate of urinary tract infections surgical slings to treat stress urinary incontinence fecal incontinence products natural and synthetic devices to treat pelvic floor and vaginal prolapse brachytherapy services devices and radioactive seeds to treat prostate cancer intermittent urinary drainage catheters and urine monitoring and collection systems ureteral stents specialty devices for stone removal catheter stabilization devices and solutions for therapeutic hypothermia. CR Bard Inc also offer oncology products such as specialty vascular access catheters and ports vascular access ultrasound devices dialysis access catheters and enteral feeding devices to treat and manage various cancers and other diseases and disorders. Its surgical specialty solutions include soft tissue repair products such as hernia repair grafts and hernia fixation devices surgical sealants for intraoperative sealing of air leaks in thoracic surgery and other products such as irrigation wound drainage and original equipment manufacturers products. CR Bard Inc sells its solutions to hospitals individual healthcare professionals extended care facilities and alternate site facilities directly as well as through hospitalsurgical supply and other medical specialty distributors. C. R. Bard Inc. was founded in 1907 and is headquartered in Murray Hill New Jersey.
CR Bard Inc has less than 12.512 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory